Htg Molecular Diagnostics Stock Current Valuation
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
Valuation analysis of HTG Molecular Diagnostics helps investors to measure HTG Molecular's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that HTG Molecular's price fluctuation is very steady at this time. Calculation of the real value of HTG Molecular Diagnostics is based on 3 months time horizon. Increasing HTG Molecular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the HTG stock is determined by what a typical buyer is willing to pay for full or partial control of HTG Molecular Diagnostics. Since HTG Molecular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HTG Stock. However, HTG Molecular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.57 | Real 0.54 | Hype 0.57 |
The intrinsic value of HTG Molecular's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HTG Molecular's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HTG Molecular Diagnostics helps investors to forecast how HTG stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HTG Molecular more accurately as focusing exclusively on HTG Molecular's fundamentals will not take into account other important factors: HTG Molecular Diagnostics Company Current Valuation Analysis
HTG Molecular's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current HTG Molecular Current Valuation | 2.56 M |
Most of HTG Molecular's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HTG Molecular Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, HTG Molecular Diagnostics has a Current Valuation of 2.56 M. This is 99.98% lower than that of the Health Care Technology sector and 99.97% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
HTG Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HTG Molecular's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HTG Molecular could also be used in its relative valuation, which is a method of valuing HTG Molecular by comparing valuation metrics of similar companies.HTG Molecular is currently under evaluation in current valuation category among its peers.
HTG Fundamentals
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| Gross Profit | (2.01 M) | |||
| EBITDA | (20.14 M) | |||
| Net Income | (21.59 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Current Ratio | 1.90 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | (17.10) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 53 | |||
| Beta | 0.99 | |||
| Market Capitalization | 1.06 M | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Working Capital | 7.38 M | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
| Z Score | -20.86 | |||
| Net Asset | 17.78 M |
About HTG Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HTG Molecular Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HTG Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HTG Molecular Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |